Annual report pursuant to Section 13 and 15(d)

Nature of Business and Basis of Presentation - Additional Information (Detail)

v3.8.0.1
Nature of Business and Basis of Presentation - Additional Information (Detail)
$ in Thousands
3 Months Ended 8 Months Ended 12 Months Ended
Aug. 01, 2017
Jan. 05, 2015
shares
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Nature Of Business And Basis Of Presentation [Line Items]                            
Accumulated deficit     $ (12,694)       $ (2,062)         $ (12,694) $ (2,062)  
Net loss     (3,740) $ (6,469) $ (169) $ (205) (486) $ (268) $ (238) $ (242) $ (828) (10,583) (1,234) $ (828)
Cash and cash equivalents at carrying value     5,284       $ 15         5,284 $ 15  
Working capital     $ 3,700                 $ 3,700    
OncoGenex Pharmaceuticals, Inc [Member]                            
Nature Of Business And Basis Of Presentation [Line Items]                            
Reverse stock split ratio 0.0909 0.0909                        
Conversion of each issued share of Achieve common stock , shares converted | shares   8,210,118